➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Harvard Business School
Boehringer Ingelheim
Colorcon

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MOVANTIK

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Movantik

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02705378 ↗ The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit Not yet recruiting AstraZeneca Phase 3 2016-05-01 Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.
NCT02705378 ↗ The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit Not yet recruiting Massachusetts General Hospital Phase 3 2016-05-01 Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.
NCT02737059 ↗ Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Recruiting AstraZeneca Phase 1 2016-05-01 This is a single center, randomized, double-blind, placebo-controlled, parallel-group, Phase I study of the effects of naloxegol, a novel mu-opioid antagonist, on gastrointestinal and colonic transit in the presence or absence of the mu-opiate, codeine. There is a need to develop effective medications for the treatment of opiate-induced constipation and other motility disorders. Currently available opiates are complicated by addictive potential and induction of troublesome constipation.
NCT02737059 ↗ Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Recruiting Michael Camilleri Phase 1 2016-05-01 This is a single center, randomized, double-blind, placebo-controlled, parallel-group, Phase I study of the effects of naloxegol, a novel mu-opioid antagonist, on gastrointestinal and colonic transit in the presence or absence of the mu-opiate, codeine. There is a need to develop effective medications for the treatment of opiate-induced constipation and other motility disorders. Currently available opiates are complicated by addictive potential and induction of troublesome constipation.
NCT02745353 ↗ Naloxegol in Cancer Opioid-Induced Constipation Not yet recruiting AstraZeneca Phase 2 2016-04-01 The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation.
NCT02745353 ↗ Naloxegol in Cancer Opioid-Induced Constipation Not yet recruiting University of California, San Diego Phase 2 2016-04-01 The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced. Also, the purpose of this study is to compare whether treatment with naloxegol versus usual care has any impact on the number of hospital or clinic visits or telephone calls to the patient's physician that are related to constipation, and to determine the patient's preference for continuing to receive naloxegol as treatment for opioid-induced constipation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Movantik

Condition Name

Condition Name for Movantik
Intervention Trials
Constipation 6
Constipation Drug Induced 2
Pelvic Prolapse 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Movantik
Intervention Trials
Constipation 8
Critical Illness 2
Disease 1
Prolapse 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Movantik

Trials by Country

Trials by Country for Movantik
Location Trials
United States 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Movantik
Location Trials
Ohio 3
Pennsylvania 2
Massachusetts 2
California 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Movantik

Clinical Trial Phase

Clinical Trial Phase for Movantik
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Movantik
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Movantik

Sponsor Name

Sponsor Name for Movantik
Sponsor Trials
AstraZeneca 8
Massachusetts General Hospital 2
Temple University 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Movantik
Sponsor Trials
Other 13
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
AstraZeneca
Harvard Business School
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.